IBDEI2VY ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,48459,0)
 ;;=I69.090^^216^2407^9
 ;;^UTILITY(U,$J,358.3,48459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48459,1,3,0)
 ;;=3^Apraxia following nontraumatic subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,48459,1,4,0)
 ;;=4^I69.090
 ;;^UTILITY(U,$J,358.3,48459,2)
 ;;=^5007420
 ;;^UTILITY(U,$J,358.3,48460,0)
 ;;=I69.890^^216^2407^10
 ;;^UTILITY(U,$J,358.3,48460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48460,1,3,0)
 ;;=3^Apraxia following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,48460,1,4,0)
 ;;=4^I69.890
 ;;^UTILITY(U,$J,358.3,48460,2)
 ;;=^5007546
 ;;^UTILITY(U,$J,358.3,48461,0)
 ;;=I69.393^^216^2407^12
 ;;^UTILITY(U,$J,358.3,48461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48461,1,3,0)
 ;;=3^Ataxia following cerebral infarction
 ;;^UTILITY(U,$J,358.3,48461,1,4,0)
 ;;=4^I69.393
 ;;^UTILITY(U,$J,358.3,48461,2)
 ;;=^5007518
 ;;^UTILITY(U,$J,358.3,48462,0)
 ;;=I69.193^^216^2407^13
 ;;^UTILITY(U,$J,358.3,48462,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48462,1,3,0)
 ;;=3^Ataxia following nontraumatic intracerebral hemorrhage
 ;;^UTILITY(U,$J,358.3,48462,1,4,0)
 ;;=4^I69.193
 ;;^UTILITY(U,$J,358.3,48462,2)
 ;;=^5007455
 ;;^UTILITY(U,$J,358.3,48463,0)
 ;;=I69.293^^216^2407^16
 ;;^UTILITY(U,$J,358.3,48463,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48463,1,3,0)
 ;;=3^Ataxia following other nontraumatic intracranial hemorrhage
 ;;^UTILITY(U,$J,358.3,48463,1,4,0)
 ;;=4^I69.293
 ;;^UTILITY(U,$J,358.3,48463,2)
 ;;=^5007487
 ;;^UTILITY(U,$J,358.3,48464,0)
 ;;=I69.093^^216^2407^14
 ;;^UTILITY(U,$J,358.3,48464,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48464,1,3,0)
 ;;=3^Ataxia following nontraumatic subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,48464,1,4,0)
 ;;=4^I69.093
 ;;^UTILITY(U,$J,358.3,48464,2)
 ;;=^5007423
 ;;^UTILITY(U,$J,358.3,48465,0)
 ;;=I69.893^^216^2407^15
 ;;^UTILITY(U,$J,358.3,48465,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48465,1,3,0)
 ;;=3^Ataxia following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,48465,1,4,0)
 ;;=4^I69.893
 ;;^UTILITY(U,$J,358.3,48465,2)
 ;;=^5007549
 ;;^UTILITY(U,$J,358.3,48466,0)
 ;;=I69.31^^216^2407^17
 ;;^UTILITY(U,$J,358.3,48466,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48466,1,3,0)
 ;;=3^Cognitive deficits following cerebral infarction
 ;;^UTILITY(U,$J,358.3,48466,1,4,0)
 ;;=4^I69.31
 ;;^UTILITY(U,$J,358.3,48466,2)
 ;;=^5007490
 ;;^UTILITY(U,$J,358.3,48467,0)
 ;;=I69.11^^216^2407^18
 ;;^UTILITY(U,$J,358.3,48467,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48467,1,3,0)
 ;;=3^Cognitive deficits following nontraumatic intcrbl hemorrhage
 ;;^UTILITY(U,$J,358.3,48467,1,4,0)
 ;;=4^I69.11
 ;;^UTILITY(U,$J,358.3,48467,2)
 ;;=^5007426
 ;;^UTILITY(U,$J,358.3,48468,0)
 ;;=I69.01^^216^2407^19
 ;;^UTILITY(U,$J,358.3,48468,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48468,1,3,0)
 ;;=3^Cognitive deficits following ntrm subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,48468,1,4,0)
 ;;=4^I69.01
 ;;^UTILITY(U,$J,358.3,48468,2)
 ;;=^5007394
 ;;^UTILITY(U,$J,358.3,48469,0)
 ;;=I69.81^^216^2407^21
 ;;^UTILITY(U,$J,358.3,48469,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48469,1,3,0)
 ;;=3^Cognitive deficits following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,48469,1,4,0)
 ;;=4^I69.81
 ;;^UTILITY(U,$J,358.3,48469,2)
 ;;=^5007521
 ;;^UTILITY(U,$J,358.3,48470,0)
 ;;=I69.21^^216^2407^20
 ;;^UTILITY(U,$J,358.3,48470,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48470,1,3,0)
 ;;=3^Cognitive deficits following oth ntrm intcrn hemorrhage
 ;;^UTILITY(U,$J,358.3,48470,1,4,0)
 ;;=4^I69.21
 ;;^UTILITY(U,$J,358.3,48470,2)
 ;;=^5007458
